TY - JOUR
T1 - Outcome of Transplant Recipients Infected with Omicron BA.1 and BA.2: A Single-Center Retrospective Study in Saudi Arabia
AU - Alshukairi, Abeer N.
AU - Aldabbagh, Yasser
AU - Adroub, Sabir
AU - Mourier, Tobias
AU - Abumelha, Khalid Y.
AU - Albishi, Ghadeer E.
AU - Alraddadi, Basem M.
AU - Al Hroub, Mohammad K.
AU - El-Saed, Aiman
AU - Ibrahim, Suzan M. Nagash
AU - Al Musawa, Mohammed
AU - Almasari, Ahlam
AU - Habahab, Wael T.
AU - Alhamlan, Fatimah S.
AU - Al-Omari, Awad
AU - Pain, Arnab
AU - Dada, Ashraf
N1 - KAUST Repository Item: Exported on 2023-01-12
Acknowledged KAUST grant number(s): BAS/1/1020-01-01
Acknowledgements: The whole genome sequence work was supported by a faculty baseline fund (BAS/1/1020-01-01), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia and King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia: COVID19 grant 2200009.We would like to thank the support of our institutions, King Faisal Specialist hospital and Research Center in Jeddah and Riyadh, King Abdullah University of Science and Technology (KAUST), Thuwal and Dr Sulaiman Al-Habib Medical Group, Riyadh, Saudi Arabia.
PY - 2023/1/10
Y1 - 2023/1/10
N2 - The outcome of transplant recipients is variable depending on the study population, vaccination status and COVID-19 variants. Our aim was to study the impact of Omicron subvariants on the mortality of transplant recipients. We reviewed the results of SARS-CoV-2 whole genome sequence of random isolates collected from 29 December 2021 until 17 May 2022 in King Faisal Specialist Hospital and Research center, Jeddah (KFSHRC-J), Saudi Arabia performed as hospital genomic surveillance program for COVID-19 variants. We included 25 transplant patients infected with confirmed Omicron variants.17 (68%) and 8 (32%) patients had Omicron BA.1 and BA.2, respectively. 12 (68%) patients had renal transplants. Only 36% of patients received three doses of COVID-19 vaccines. 23 (92%) patients required hospitalization. 20 (80%) patients survived and 6 (25%) required intensive care unit (ICU) admission. Among ICU patients, 66.7% were more than 50 years, 50% had two to three comorbidities and 5 out of 6 (83%) died. The mortality of transplant patients infected with Omicron variants in our cohort was higher than other centers as a limited number of patients received booster vaccines. Optimizing booster vaccination is the most efficient method to improve the mortality of COVID-19 in transplant recipients recognizing the inefficacy of monoclonal antibodies in the presence of SARS-CoV-2 emerging variants. We did not show a difference in mortality in transplant patients infected with Omicron BA.1 and BA.2 knowing the limitation of our sample size.
AB - The outcome of transplant recipients is variable depending on the study population, vaccination status and COVID-19 variants. Our aim was to study the impact of Omicron subvariants on the mortality of transplant recipients. We reviewed the results of SARS-CoV-2 whole genome sequence of random isolates collected from 29 December 2021 until 17 May 2022 in King Faisal Specialist Hospital and Research center, Jeddah (KFSHRC-J), Saudi Arabia performed as hospital genomic surveillance program for COVID-19 variants. We included 25 transplant patients infected with confirmed Omicron variants.17 (68%) and 8 (32%) patients had Omicron BA.1 and BA.2, respectively. 12 (68%) patients had renal transplants. Only 36% of patients received three doses of COVID-19 vaccines. 23 (92%) patients required hospitalization. 20 (80%) patients survived and 6 (25%) required intensive care unit (ICU) admission. Among ICU patients, 66.7% were more than 50 years, 50% had two to three comorbidities and 5 out of 6 (83%) died. The mortality of transplant patients infected with Omicron variants in our cohort was higher than other centers as a limited number of patients received booster vaccines. Optimizing booster vaccination is the most efficient method to improve the mortality of COVID-19 in transplant recipients recognizing the inefficacy of monoclonal antibodies in the presence of SARS-CoV-2 emerging variants. We did not show a difference in mortality in transplant patients infected with Omicron BA.1 and BA.2 knowing the limitation of our sample size.
UR - http://hdl.handle.net/10754/686928
UR - https://link.springer.com/10.1007/s44197-023-00084-6
U2 - 10.1007/s44197-023-00084-6
DO - 10.1007/s44197-023-00084-6
M3 - Article
C2 - 36626091
SN - 2210-6006
JO - Journal of Epidemiology and Global Health
JF - Journal of Epidemiology and Global Health
ER -
